Back to discover
Drug

Cholecalciferol

In clinical development
ClassVitamin D receptor agonistEmerging researchLate-stage developmentSteady momentum
Also known as (+)-vitamin D3, Activated 7-dehydrocholesterol, Animi-3 with Vitamin D, CC+70 more

(+)-vitamin D3, Activated 7-dehydrocholesterol, Animi-3 with Vitamin D, CC, Cal-Quick, Calafol Rx, Calcarb with D, Calcet, Calciol, Caltrate 600 with Iron and Vitamin D, Caltrate Gummy Bites, Caltrate Plus D, Colecalciferol, Colecalciferolum, D-Vi-Sol, D3, D3 + K2, D3 - cholecalciferol, D3 - colecalciferol, D3 Dots, Decalcitrol, Decara, Delta D3, Dialyvite Vitamin D3 Max, Encora AM Tablet, Encora PM Tablet, Folditam, Folgard OS, Folixate, Fosamax Plus D, Infuvite, Infuvite Pediatric, Lactocal, MVC-Fluoride, Maximum D3, Multi-Delyn, Natafort, Nephrocaps QT, Oleovitamin D3, Os-Cal 500 + D, Os-Cal 500 with D, Osteo-Poretical, Ostercal-D, Oysco 500 with D, Oysco D, Poly-Vi-Sol, Poly-Vi-Sol with Iron, PreNexa, ReliOn Glucose, Replesta NX, Thera-D, Tri-Vi-Sol, Tri-Vi-Sol with Iron, VITD - Colecalciferol, VITD - cholecalciferol, Vitafol-One, Vital E- A + D3, Vital E- Newborn, Vital E- Repro, Vitamin D (Cholecalciferol), Vitamin D 3, Vitamin D-3, Vitamin D3, Vitamin D>3<, Vitamin-D3, cholecalciferol (vitamin D3), (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol, Calcium Carbonate with Vitamin D3, Calcium Citrate with Vitamin D3, Calcium Citrate+D3, Calvite P/D, Cholecalciferolum, Oysco D with Calcium, Viactiv Calcium Plus D.

6
Research papers
5
Active clinical trials
Vitamin D3 receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension

Clinical trial2025-11-01Primary completion · ClinicalTrials.gov

Vitamin D<sub>3</sub> Receptors and Metabolic Enzymes in Hen Reproductive Tissues.

Research2023-12-03International journal of molecular sciences

A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Research2010-01-07Clinical journal of the American Society of Nephrology : CJASN

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Cholecalciferol
Aliases & brands
(+)-vitamin D3Activated 7-dehydrocholesterolAnimi-3 with Vitamin DCCCal-QuickCalafol RxCalcarb with DCalcetCalciolCaltrate 600 with Iron and Vitamin DCaltrate Gummy BitesCaltrate Plus DColecalciferolColecalciferolumD-Vi-SolD3D3 + K2D3 - cholecalciferolD3 - colecalciferolD3 DotsDecalcitrolDecaraDelta D3Dialyvite Vitamin D3 MaxEncora AM TabletEncora PM TabletFolditamFolgard OSFolixateFosamax Plus DInfuviteInfuvite PediatricLactocalMVC-FluorideMaximum D3Multi-DelynNatafortNephrocaps QTOleovitamin D3Os-Cal 500 + DOs-Cal 500 with DOsteo-PoreticalOstercal-DOysco 500 with DOysco DPoly-Vi-SolPoly-Vi-Sol with IronPreNexaReliOn GlucoseReplesta NXThera-DTri-Vi-SolTri-Vi-Sol with IronVITD - ColecalciferolVITD - cholecalciferolVitafol-OneVital E- A + D3Vital E- NewbornVital E- ReproVitamin D (Cholecalciferol)Vitamin D 3Vitamin D-3Vitamin D3Vitamin D>3<Vitamin-D3cholecalciferol (vitamin D3)(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-olCalcium Carbonate with Vitamin D3Calcium Citrate with Vitamin D3Calcium Citrate+D3Calvite P/DCholecalciferolumOysco D with CalciumViactiv Calcium Plus D
RxNorm CUI
2418
ChEMBL ID
CHEMBL1042
ATC codes
A11CC05
UNII
1C6V77QF41
Primary mechanism
Vitamin D receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vitamin D3 receptor
VDR · P11473
AGONISTVitamin D receptor agonist

Clinical trials

186 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
186
registered trials across all phases
LATEST COMPLETION 2025
5
Active studies
3
Recruiting
124
Late-stage (III+)
130
Completed
51
Discontinued
PHASE DISTRIBUTIONn = 186
Early Phase 12Phase 114Phase 1 / 23Phase 243Phase 2 / 311Phase 338Phase 437Phase N / A38

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

6 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20082024
Most influential
Recent papers
Major research themes8
Vitamin D Deficiency2Cardiovascular Diseases1Chickens1Diabetes Mellitus, Type 11Diabetes Mellitus, Type 21Infertility1Insulin Resistance1Metabolic Syndrome1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences2
  • Andrology1
  • Clinical journal of the American Society of Nephrology : CJASN1
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1
  • Journal of the American Society of Nephrology : JASN1
Leading researchers
  • Amodeo S1
  • Argano C1
  • Binongo JN1
  • Blomberg Jensen M1
  • Chandra P1
  • Corrao S1
  • Grzesiak M1
  • Holt R1
Leading institutions
free-text, unnormalised
  • Copenhagen University Hospital - Herlev and Gentofte1
  • Copenhagen University Hospital - Rigshospitalet1
  • Department of Clinical Medicine1
  • Doctoral School of Exact and Natural Sciences1
  • Emory University1
  • Indiana University School of Medicine1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Acts on the same molecular target as Cholecalciferol, with 9 overlapping disease areas.

Shared target9 shared diseases3 shared papers

Studied across 8 of the same disease areas as Cholecalciferol in the shared literature.

8 shared diseases1 shared paper

Studied across 7 of the same disease areas as Cholecalciferol in the shared literature.

7 shared diseases1 shared paper

Studied across 5 of the same disease areas as Cholecalciferol in the shared literature.

5 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials